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Venous thromboembolism (VTE) is increasingly prevalent despite efforts to prevent the disease. The number of adults 
with VTE in the United States is projected to double from 0.95 
million in 2006 to 1.82 million in 2050, mainly as a result of the 
expansion and aging of the population.1 Vitamin K antagonists 
have been the mainstay in the treatment of VTE after an initial 
course of parenteral anticoagulation. Recent studies have dem-
onstrated that novel oral thrombin or factor Xa inhibitors can 
be used for long-term anticoagulation in patients with VTE,2–4 
atrial fibrillation,5–7 or acute coronary syndromes8 without the 
need for laboratory monitoring or dose adjustments. The incon-
venience of vitamin K antagonists for both patients and health-
care providers is thereby avoided. Another goal is to decrease 
Background—Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in 
a previous trial. We undertook this study to extend those findings.
Methods and Results—In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with 
low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with 
warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months 
of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; 
hazard ratio, 1.08; 95% confidence interval [CI], 0.64–1.80; absolute risk difference, 0.2%; 95% CI, −1.0 to 1.3; P<0.001 
for the prespecified noninferiority margin for both criteria). The safety end point, major bleeding, occurred in 15 patients 
receiving dabigatran (1.2%) and in 22 receiving warfarin (1.7%; hazard ratio, 0.69; 95% CI, 0.36–1.32). Any bleeding 
occurred in 200 dabigatran (15.6%) and 285 warfarin (22.1%; hazard ratio, 0.67; 95% CI, 0.56–0.81) patients. Deaths, 
adverse events, and acute coronary syndromes were similar in both groups. Pooled analysis of this study RE-COVER II 
and the RE-COVER trial gave hazard ratios for recurrent VTE of 1.09 (95% CI, 0.76–1.57), for major bleeding of 0.73 
(95% CI, 0.48–1.11), and for any bleeding of 0.70 (95% CI, 0.61–0.79).
Conclusion—Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the 
treatment of acute VTE.
Clinical Trial Registration—URL: www.clinicaltrials.gov. Unique identifiers: NCT00680186 and NCT00291330.   
(Circulation. 2014;129:764-772.)
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the bleeding risk associated with vitamin K antagonists,9 which 
is important because warfarin has been implicated in 33% of 
emergency hospitalizations for adverse drug events.10
Dabigatran etexilate (hereafter referred to as dabigatran) is 
an orally administered direct thrombin inhibitor with an effi-
cacy similar to that of warfarin in the treatment and second-
ary prevention of VTE and with a reduced risk for major and 
clinically relevant nonmajor bleeding (hereafter referred to as 
clinically relevant bleeding).4,11 On the basis of the low rate 
of recurrent VTE observed during recruitment to the first trial 
(RE-COVER), we initiated this study (RE-COVER II) to con-
firm the results and to allow more precise subgroup analyses 
using pooled data from the 2 trials.
Methods
Study Design
The design of this trial was essentially identical to that of the first study 
with dabigatran for the treatment of acute VTE.4 Briefly, we used a 
randomized, double-blind, double-dummy design to compare dabiga-
tran 150 mg twice daily with warfarin, adjusted to maintain an inter-
national normalized ratio (INR) of 2.0 to 3.0 during 6 months, after 
initial parenteral anticoagulation. The study was designed, conducted, 
and funded and the data were analyzed by Boehringer Ingelheim and 
the steering committee, the members of which vouch for the complete-
ness and accuracy of the data and the analyses reported here. The pro-
tocol and all amendments were approved by the institutional review 
board at each participating clinical center, and all patients provided 
informed consent. A central adjudication committee, the members of 
which were unaware of the treatment assignments, classified all sus-
pected outcome events, bleeding events, and deaths. An independent 
data and safety monitoring board periodically reviewed the efficacy 
and safety outcomes. The steering committee wrote the manuscript 
and made the decision to submit it for publication.
Study Patients
We recruited patients at 208 study sites in 31 countries worldwide. 
The inclusion and exclusion criteria were the same as previously 
described4 except that baseline aminotransferases had to exceed 
3 times rather than 2 times the local upper limit of the normal for 
patients to be excluded. The diagnosis of proximal deep vein throm-
bosis or pulmonary embolism was established objectively before 
randomization. Additional screening for asymptomatic deep vein 
thrombosis and pulmonary embolism was performed within 72 hours 
after randomization.4
Random Assignment and Treatment
Patients were randomized by use of an interactive voice response sys-
tem and a computer-generated randomization scheme in blocks of 4. 
The randomization was stratified according to the presence or absence 
of symptomatic pulmonary embolism or active cancer. Patients 
were assigned in a 1:1 ratio to receive active fixed-dose dabigatran 
150 mg twice daily and warfarin-like placebo or active warfarin and 
dabigatran-like placebo. Treatment with a parenteral anticoagulant 
(unfractionated heparin or low-molecular-weight heparin) was gen-
erally started before randomization. On the day of randomization, 
warfarin or warfarin-like placebo was added to the parenteral treat-
ment and adjusted to achieve an INR of 2.0 to 3.0 with the use of a 
point-of-care instrument that provided an encrypted INR. An interac-
tive voice-response system provided a true or sham INR. This was the 
single-dummy phase, which lasted for at least 5 days and until the true 
or sham INR had been ≥2.0 for 2 consecutive measurements. Then, 
parenteral anticoagulation was stopped and the first dose of dabigatran 
was given within 2 hours before the time that the next dose of subcuta-
neous parenteral therapy would have been due or at the time of discon-
tinuation of intravenous unfractionated heparin. The study drugs were 
then given for 6 months from randomization (double-dummy phase).
Follow-Up and Outcome Measures
We assessed the patients at 7 days and monthly for 6 months. An 
additional visit occurred 30 days after treatment completion unless 
the patient had discontinued study medication prematurely or was 
enrolled in a trial of extended treatment with anticoagulants.
Suspected recurrent VTE had to be objectively verified, prefer-
ably with the same method as for the index event. Major bleeding 
was defined according to the International Society on Thrombosis 
and Haemostasis criteria.12 Other bleeding was classified as clini-
cally relevant nonmajor bleeding (defined in the online-only Data 
Supplement, available with the full text of this article) or as nuisance 
bleeding. The protocol stated as hierarchically equal safety outcomes 
major bleeding, major or clinically relevant nonmajor bleeding, and 
any bleeding. We had not planned for independent central adjudica-
tion of acute coronary syndromes, but this decision was revised by the 
steering committee and performed at the end of the trial, after data-
base lock but while the committee was still blinded to the treatment 
allocation. Other adverse events, laboratory measures, and adherence 
(quantified by capsule counts) were assessed routinely.
Statistical Analysis
The trial was designed to demonstrate that dabigatran was as effective 
as (ie, noninferior to) warfarin and to compare the safety of the 2 drug 
regimens during 6 months of treatment of acute VTE. We determined 
the sample size on the basis of an expected rate of recurrent VTE of 
2% in each group during 6 months,2,13,14 while requiring a power of 
90% to exclude a hazard ratio of 2.75, an absolute risk increase of 
3.6 percentage points for the primary outcome with dabigatran, and a 
1-sided α level of 0.025. With a possible 20% loss to follow-up dur-
ing 6 months allowed for, the required sample size was 2550 patients, 
with 1275 patients per group and a total of at least 46 events. The 
noninferiority margins in this study were similar to those in contem-
porary VTE trials for both the hazard ratio3,11,15 and the absolute risk 
increase,11,16–19 although in more recently designed trials, the noninfe-
riority margin for the risk estimate has decreased to 1.8 (relative risk 
in the Apixaban for the Initial Management of Pulmonary Embolism 
and Deep-Vein Thrombosis as First-Line Therapy [AMPLIFY])20 and 
1.5 (hazard ratio in Hokusai-VTE).21
The population analyzed for efficacy consisted of all randomized 
patients who took at least 1 dose of the study drug. The primary 
analysis for efficacy was a comparison between the groups of the 
time to the first occurrence of the composite end point of symp-
tomatic VTE or death associated with VTE in the 6 months after 
randomization. This was assessed by the hazard ratio, calculated 
with the use of the Cox model; the difference in risk was calculated 
with the use of Kaplan-Meier estimates. Both summary statistics 
were adjusted for the presence or absence of pulmonary embolism 
and active cancer at baseline. The interaction between active can-
cer and symptomatic pulmonary embolism was also included in the 
Cox model. We tested for noninferiority by comparing the upper 
boundary of the 95% confidence interval (CI) for the hazard ratio 
with the predefined margin of 2.75 and for the difference in absolute 
risk with the predefined margin of 3.6 percentage points. If nonin-
feriority was confirmed with both criteria, testing for superiority of 
dabigatran was to be performed.
The safety population also consisted of all randomized patients 
who took at least 1 dose of the study drug, but this analysis was 
according to the actual treatment received and was from the first dose 
of trial treatment until 6 days after the trial treatment. We excluded 
the 6-day period after the last dose if patients were enrolled in a trial 
on extended treatment.
After the trial results were known, the steering committee decided 
to present pooled data of the primary and secondary efficacy and 
safety outcomes from this and the previous trial that compared dabi-
gatran and warfarin for treatment of acute VTE. Minor corrections 
of the numerators were made, as explained in the online-only Data 
Supplement. The hazard ratios were obtained from a Cox model 
assuming different baseline hazards for the 2 studies and a common 
treatment effect. Statistical analyses were performed with SAS ver-
sion 9.2 (SAS Institute Inc, Cary, NC).
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Results
From June 2008 through October 2010, we randomized 2589 
patients; 66% were from Europe or North America, and 20% 
were from Asia. Fourteen patients in the dabigatran group and 
7 in the warfarin group did not receive any study medication 
(10 did not meet the inclusion criteria or met the exclusion cri-
teria, 9 withdrew consent, and 2 had an adverse event; Figure I 
in the online-only Data Supplement). Therefore, 1279 patients 
in the dabigatran group and 1289 patients in the warfarin group 
were included in the analysis of efficacy. One patient was 
assigned to receive warfarin but received dabigatran through-
out the study. One patient in each group mistakenly received 
the opposite treatment for the first month, after which time the 
mistake was corrected. None of these 3 patients had any VTE, 
Table 1. Characteristics of the Patients and Treatments*
 Characteristic Dabigatran (n=1280) Warfarin (n=1288) P Value
Age, y 54.7±16.2 55.1±16.3 0.39
  Median 56 57
  Range 18–92 18–93
Female sex, n (%) 499 (39) 512 (39.8) 0.69
Race, n (%)† 1.00
  White 993 (77.6) 999 (77.6)
  Black 19 (1.5) 19 (1.5)
  Asian 267 (20.9) 270 (21.0)
Weight, kg 83.2±19.7 82.9±19.6 0.69
  Median 80 81
  Range 36–184 35–210
Body mass index, kg/m2 28.4±5.8 28.4±5.8 0.89
Estimated creatinine clearance, mL/min‡ 108.2±43.7 107.1±41.1 0.50
Type of index event, n (%) 0.85
  Deep vein thrombosis only 877 (68.5) 873 (67.8)
  Pulmonary embolism only 298 (23.3) 297 (23.1)
  Both deep vein thrombosis and pulmonary embolism 104 (8.1) 117 (9.1)
  Neither deep vein thrombosis nor pulmonary embolism§ 1 (0.1) 1 (0.1)
Cancer at baseline, n (%) 50 (3.9) 50 (3.9) 0.98
Previous venous thromboembolism, n (%) 247 (19.3) 203 (15.8) 0.02
Concomitant use of acetylsalicylic acid, n (%) 130 (10.2) 112 (8.7) 0.20
Parenteral anticoagulation
  Total duration of treatment, d 9.4±3.8 9.6±4.1
  Treatment after randomization in the single-dummy phase, d‖ 6.8±3.4 7.1±3.7
  Unfractionated heparin, n (%) 198 (15.5) 207 (16.1)
  Low-molecular-weight heparin, n (%) 1133 (88.5) 1147 (89.1)
  Fondaparinux, n (%) 32 (2.5) 21 (1.6)
Double-dummy phase¶
  Exposure to study drug, d 164.4±47.6 164.0±48.5
  Adherence to study regimen, n (%)# 1251 (97.7) 1266 (98.3)
  Time that INR was in the therapeutic range, % NA 56.9±21.9
INR indicates international normalized ratio; and NA, not applicable
*Plus-minus values are mean±SD. The numbers in the 2 groups represent the number of patients treated with dabigatran or warfarin rather than the number 
randomized to the treatment (1 patient who was assigned to receive dabigatran mistakenly received warfarin during the entire study, and 1 per group received the 
opposite treatment the first month). The P values were calculated with the use of Student t test for creatinine clearance and body mass index, the Wilcoxon-Mann-
Whitney test for age and weight, the Fisher exact test for race and type of index event, and the χ2 test for sex, cancer, concomitant use of acetylsalicylic acid, and 
previous venous thromboembolism. 
†Race was determined by the investigator; data were missing for 1 patient in the dabigatran group.
‡Creatinine clearance was estimated according to the Cockcroft-Gault method.
§In the case of 1 patient in each group, the diagnosis of venous thromboembolism was made locally and was subsequently not confirmed by the central adjudication 
committee.
‖In the single-dummy phase, patients received a parenteral anticoagulant agent and warfarin or warfarin-like placebo. Some patients received >1 parenteral 
anticoagulant during this phase.
¶In the 6-month double-dummy phase, patients received only the oral treatment (dabigatran and warfarin-like placebo or warfarin and dabigatran-like placebo).
#Adherence was assumed if a pill count of dabigatran or the dabigatran placebo indicated an intake of between 80% and 120% of the prescribed dose.
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bleeding, or serious adverse events. In the safety analysis, we 
therefore had 1280 patients in the dabigatran group and 1288 
patients in the warfarin group. There were no significant dif-
ferences between the groups in baseline characteristics except 
for a higher proportion with previous VTE in the dabigatran 
group (Table 1).
Treatment and Follow-Up
The median duration of initial parenteral anticoagulation was 
9.4 days in the dabigatran group and 9.6 days in the warfarin 
group (Table 1). In the warfarin group, the mean time in the 
therapeutic range (INR, 2.0–3.0) was 57%, increasing from 
51% in month 1 and 56% in month 2 to between 59% and 62% 
per month during months 3 through 6. The INR was below the 
therapeutic range 24% of the time and above the therapeutic 
range 19% of the time.
The study drug was stopped before planned treatment com-
pletion in 188 patients (14.7%) in the dabigatran group (102 
because of an adverse event, 39 because of nonadherence, 
6 because of loss to follow-up, 33 because of withdrawal of 
consent, and 8 for other reasons) and in 182 patients (14.1%) 
in the warfarin group (101 because of an adverse event, 37 
because of nonadherence, 3 because of loss to follow-up, 38 
because of withdrawal of consent, and 3 for other reasons). 
The planned observation time for analysis of efficacy was not 
completed in 125 patients (9.8%) in the dabigatran group (47 
because of an adverse event, 31 because of nonadherence, 11 
because of loss to follow-up, 32 because of withdrawal of con-
sent, and 4 for other reasons) and in 116 patients (9.0%) in the 
warfarin group (44 because of an adverse event, 26 because 
of nonadherence, 6 because of loss to follow-up, 39 because 
of withdrawal of consent, and 1 for other reasons). After 6 
months of treatment, 61 patients from the dabigatran group 
and 65 from the warfarin group gave additional informed 
consent and were randomly assigned a second time to receive 
treatment with dabigatran or warfarin as extended secondary 
prophylaxis as part of the double-blind RE-MEDY study.
Efficacy
Recurrent nonfatal or fatal VTE was confirmed after central 
adjudication in 30 patients in the dabigatran group (2.3%) and 
in 28 patients in the warfarin group (2.2%; hazard ratio, 1.08; 
95% CI, 0.64–1.80; Figure 1). The difference in risk was 0.2 
percentage points (95% CI, −1.0 to 1.3) in favor of warfarin. 
Dabigatran was noninferior to warfarin for the prevention of 
recurrent or fatal VTE (P<0.001 for both hazard ratio and dif-
ference in absolute risk criteria). Efficacy results were con-
sistent in all the predefined subgroups (data not shown). The 
results by the components of the primary end point are shown 
in Table 2.
Safety
Fifteen patients in the dabigatran group (1.2%) and 22 patients 
in the warfarin group (1.7%) had major bleeding events (haz-
ard ratio, 0.69; 95% CI, 0.36–1.32; Figure 2). The difference 
in risk was –0.6 percentage points (95% CI, −1.6 to 0.3). The 
sites of major bleeding events in the dabigatran group were 
gastrointestinal (6 events), intracranial (2), retroperitoneal (2), 
urogenital (2), intra-articular (1), and other (3), and the sites in 
the warfarin group were gastrointestinal (10 events), urogeni-
tal (7), intracranial (2), intramuscular (1), and other (4). Some 
patients had major bleeding from >1 site. We observed major 
or clinically relevant nonmajor bleeding less often in the dabi-
gatran group than in the warfarin group (hazard ratio, 0.62; 
95% CI, 0.45–0.84) and similarly any bleeding less often in 
the dabigatran group than in the warfarin group (hazard ratio, 
0.67; 95% CI, 0.56–0.81; Table 2). The incidence of differ-
ent categories of adverse events was similar in the 2 treatment 
groups (Table 2). Dyspepsia was the only drug-related adverse 
event that was more common in the dabigatran group (1.0%) 
than in the warfarin group (0.2%).
Pooled Analysis
For the 2 studies combined, the pooled hazard ratio for recur-
rent VTE was 1.09 (95% CI, 0.76–1.57) for dabigatran com-
pared with warfarin, with no suggestion that this differed 
according to whether patients presented with or without 
symptomatic pulmonary embolism or with or without can-
cer. Pooled event rates for components of the efficacy and 
safety outcomes are shown in Table 3. With age analyzed as 
a continuous variable, there was evidence that the efficacy of 
dabigatran compared with warfarin was somewhat lower in 
younger patients and higher in older patients (P=0.099 for 
interaction; Figure 3A), with equal efficacy at ≈60 years of 
age. At all ages, the 95% CI for the estimated hazard ratio 
included 1.0, suggesting that the difference in efficacy was not 
statistically significant at any age. The corresponding analysis 
for the safety outcome of clinically relevant bleeding showed 
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Figure 1. Cumulative risk of recurrent venous 
thromboembolism or related death during 6 months 
of treatment among patients randomly assigned to 
dabigatran or warfarin.
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Table 2. Efficacy and Bleeding Outcomes
 Outcome Dabigatran (n=1279) Warfarin (n=1289) Hazard Ratio (95% CI)*
Efficacy analysis†
  Primary end point of venous thromboembolism or related death, n subjects (%)
   During 6 mo 30 (2.3) 28 (2.2) 1.08 (0.64–1.80)
   During the study period plus an additional 30-d follow-up‡ 34 (2.7) 30 (2.3) 1.13 (0.69–1.85)
  Secondary end point, n subjects (%)
   Symptomatic deep vein thrombosis 25 (2.0) 17 (1.3) 1.48 (0.80–2.74)
   Symptomatic nonfatal pulmonary embolism 7 (0.5) 13 (1.0) 0.54 (0.21–1.35)
   Death related to pulmonary embolism 3 (0.2)§ 0 (0.0)
   All deaths 25 (2.0) 25 (1.9) 0.98 (0.56–1.71)
Safety analysis‖
  Major bleeding event, n subjects (%) 15 (1.2) 22 (1.7) 0.69 (0.36–1.32)
  Fatal event, n events 0 1 (0.1)
  Bleeding into critical organ, n events 6 4
   Intracranial 2 2
   Retroperitoneal 2 0
   Intra-articular 1 0
   Intramuscular 0 1
   Other 1 1
  Event resulting in fall in hemoglobin level or need for blood transfusions, n subjects (%)¶ 13 (1.0) 19 (1.5)
  Major or clinically relevant nonmajor bleeding event, n subjects (%) 64 (5.0) 102 (7.9) 0.62 (0.45–0.84)
  Any bleeding event, n subjects (%) 200 (15.6) 285 (22.1) 0.67 (0.56–0.81)
  Sites of bleeding, n events#
   Intracranial 2 6
   Intraocular 5 14
   Retroperitoneal 3 1
   Intra-articular 3 0
   Pericardial 0 1
   Intramuscular 6 20
   Gastrointestinal 48 33
   Urogenital 51 75
   Nasal 43 76
   Other 160 255
  Any adverse event, n subjects (%) 852 (66.6) 916 (71.1)
  Serious adverse event, n subjects (%) 156 (12.2) 153 (11.9)
  Event leading to discontinuation of study drug, n subjects (%) 100 (7.8) 100 (7.8) 1.00 (0.76–1.32)
  Acute coronary syndromes, n (%)** 4 (0.3) 2 (0.2)
   Myocardial infarction 4 (0.3) 2 (0.2)
  ALT >3× ULN plus bilirubin >2× ULN, n subjects (%) 1 (0.1) 2 (0.2)
ALT indicates alanine aminotransferase; CI confidence interval; and ULN, upper limit of normal.
*The hazard ratio was estimated with the use of the Cox model, including treatment, active cancer at baseline, symptomatic pulmonary embolism at baseline, and 
the interaction between active cancer and symptomatic pulmonary embolism at baseline as factors.
†The efficacy analysis was based on the number of randomly assigned patients who received at least 1 dose of the study drug. Events that occurred within 6 months 
after randomization were counted as events in the analysis, regardless of early discontinuation of study drug.
‡The extension of the study period to the end of follow-up was prespecified as the primary analysis for the hazard ratio in the statistical analysis plan of the trial. 
Because this period is >6 months, it does not reflect the true incidence of the end point after anticoagulation was discontinued because >60 patients in each group were 
enrolled in an extended-treatment study with double-blind design and additional patients received open-label anticoagulants.
§Two fatal events occurred during the single-dummy phase, that is, before dabigatran was started.
‖The safety analysis of bleeding events was performed on the basis of the number of patients treated with dabigatran (1280) or warfarin (1288) rather than the 
number assigned to the treatment (see footnote for Table 1). Events that occurred from first to last intake of any study drug plus a 6-day washout period were included.
¶Included in this category were patients in whom there was a reduction in hemoglobin level of at least 20 g/L or patients who required a transfusion of at least 2 U 
whole blood or red cells.
#Patients may have had >1 type or site of bleeding event.
**Included in this category are acute coronary syndromes classified as definite or likely by the independent adjudication committee.
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that the risk reduction with dabigatran was influenced by age 
(P=0.010 for interaction; Figure 3B); the risk reduction was 
higher with dabigatran (compared with warfarin) in younger 
patients, and at ≈85 years of age, the effect changed, so the 
risk reduction with warfarin tended to become higher (com-
pared with dabigatran).
Sex, ethnicity, geographical region, body mass index, cre-
atinine clearance, history of previous VTE, or concomitant 
use of P-glycoprotein inhibitors, acetylsalicylic acid, or non-
steroid anti-inflammatory drugs did not influence the treat-
ment effect (tests of interaction not statistically significant at 
the 5% level; Figure II in the online-only Data Supplement). 
Figure 2. Cumulative risks of 
a first event of major bleeding 
(data lines) and of any bleeding 
among patients randomly 
assigned to dabigatran or 
warfarin.
Table 3. Efficacy and Safety Outcomes in Pooled Analysis of RE-COVER4 and RE-COVER II on Treatment of Acute Venous 
Thromboembolism
Dabigatran (n=2553) Warfarin (n=2554) Hazard Ratio (95% CI)*
Outcome: efficacy
  Primary end point of venous thromboembolism or related death, n subjects (%)
   During 6 mo 60 (2.4) 55 (2.2) 1.09 (0.76–1.57)
   During the study period plus an additional 30-d follow-up 68 (2.7) 62 (2.4) 1.09 (0.77–1.54)
   Symptomatic deep vein thrombosis† 40 (1.6) 34 (1.3)
   Symptomatic nonfatal pulmonary embolism† 18 (0.7) 18 (0.7)
   Death related to pulmonary embolism† 2 (0.1) 3 (0.1)
   All deaths 46 (1.8) 46 (1.8) 1.0 (0.67–1.51)
Outcome: safety
  From the start of any study drug (single- and double-dummy periods)
   Major bleeding event, n subjects (%) 37 (1.4) 51 (2.0) 0.73 (0.48–1.11)
   Intracranial bleeding 2 (0.1) 5 (0.2)
   Major or clinically relevant nonmajor bleeding event, n subjects (%) 136 (5.3) 217 (8.5) 0.62 (0.50–0.76)
   Any bleeding event, n subjects (%) 411 (16.1) 567 (22.2) 0.70 (0.61–0.79)
  From the start of the oral drug only (double-dummy period only)
   Major bleeding event, n subjects (%) 24 (1.0) 40 (1.6) 0.60 (0.36–0.99)
   Intracranial bleeding 2 (0.1) 4 (0.2)
   Major or clinically relevant nonmajor bleeding event, n subjects (%) 109 (4.4) 189 (7.7) 0.56 (0.45–0.71)
   Any bleeding event, n subjects (%) 354 (14.4) 503 (20.4) 0.67 (0.59–0.77)
  Acute coronary syndrome, n subjects (%)
   Any 9 (0.4) 5 (0.2)
   Myocardial infarction 8 (0.3) 4 (0.2)
RE-COVER indicates Efficacy and Safety of Dabigatran Compared to Warfarin for 6-Month Treatment of Acute Symptomatic Venous Thromboembolism; and RE-COVER 
II, Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate Versus Warfarin for 6-Month Treatment for Acute Symptomatic Venous Thromboembolism.
*The hazard ratio was estimated with the use of the Cox model with factor treatment stratified by study, assuming different baseline hazards per study.
†These are the events contributing to the primary end point. In the case of a patient suffering 2 different events, the first event is counted (a detailed explanation is 
given in the online-only Data Supplement).
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Likewise, these variables or a history of bleeding did not influ-
ence the risk for major bleeding or any bleeding with dabiga-
tran compared with warfarin (data not shown).
The timing of the initiation of oral anticoagulant therapy 
in relation to the parenteral anticoagulant differs between 
warfarin and dabigatran owing to differences in their onset 
of action. Therefore, 2 safety comparisons were made: from 
the start of any study drug (from single-dummy period) and 
from the start of oral drug only (double-dummy period, after 
warfarin had reached therapeutic levels). Regardless of the 
calculation, pooled data from RE-COVER and RE-COVER II 
consistently showed a profile of less bleeding with dabigatran 
than with warfarin (Table 3).
Discussion
This study, RE-COVER II, confirms the results of RE-COVER, 
with noninferiority of dabigatran to warfarin in the prevention 
of recurrent VTE and with superiority of dabigatran for clini-
cally relevant bleeding and for any bleeding. There is also a 
similar trend for fewer major bleedings with dabigatran. The 
RE-COVER II and RE-COVER studies differed in ethnic 
composition of the study populations, with more Asians in the 
current trial (20% versus 3%). There were also fewer patients 
with previous VTE in the present study (18% versus 26% in 
RE-COVER). In the pooled analysis of dabigatran versus war-
farin, which included 1602 patients treated for symptomatic 
pulmonary embolism, efficacy was maintained with dabiga-
tran (Figure II in the online-only Data Supplement).
Subgroup analyses of the pooled data indicated no need for 
dose adjustment of dabigatran according to demographic char-
acteristics or concomitant medication use. The only level at 
which drug interactions with dabigatran have been described 
is with the permeability glycoprotein,22 which transports dabi-
gatran into the intestinal lumen. Although only 100 patients 
received dabigatran and a permeability glycoprotein inhibi-
tor in the pooled analysis, there was no apparent increase in 
bleeding in this subset. Similarly, we did not find any evidence 
of an increased risk in bleeding with dabigatran in patients 
>75 years of age, with creatinine clearance of 30 to 49 mL/
min, or with previous bleeding events.
The incidence of acute coronary syndromes was numeri-
cally higher with dabigatran than with warfarin, although not 
A
B
Figure 3. Hazard ratios with 
dabigatran, depending on age 
as a continuous variable, for 
the primary efficacy outcome 
(A) and for major or clinically 
relevant nonmajor bleeding 
(B). Pooled analysis of 
RE-COVER4 and RE-COVER 
II. VTE indicates venous 
thromboembolism.
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statistically significant, as also seen in other recent trials.11,23 
The absolute risk increase was 0.2%, which should be bal-
anced against the lower risk of intracranial hemorrhage that 
has been consistently observed with dabigatran compared 
with warfarin.5,11
The results in the RE-COVER trials can now be compared 
with those of the factor Xa inhibitors apixaban (AMPLIFY),20 
rivaroxaban (EINSTEIN DVT study,3 EINSTEIN PE study),24 
and edoxaban  (Hokusai-VTE)21 for similar patient popula-
tions. Dabigatran and edoxaban were started after initial treat-
ment with a parenteral anticoagulant and then given at a fixed 
dose and thus have not been studied as monotherapy for the 
treatment of VTE. Apixaban and rivaroxaban were given with-
out mandatory initial parenteral anticoagulant but at a higher 
dose for 1 or 3 weeks, respectively, and then lowered to a 
maintenance dose. All 4 drugs showed noninferiority versus 
warfarin in terms of efficacy. In RE-COVER,4 RE-COVER 
II, and Hokusai-VTE, there was a significant reduction in the 
combination of major and clinically relevant nonmajor bleed-
ing (hazard ratio, 0.63, 0.62, and 0.81, respectively) but not 
of major bleeding alone. In the pooled analysis, we found a 
marginally significant reduction of major bleeding while the 
patients were actually treated with dabigatran (double-dummy 
period). There was a significant reduction in major bleeding 
with rivaroxaban in the pulmonary embolism population (haz-
ard ratio, 0.49)24 and in both major and clinically relevant 
nonmajor bleeding with apixaban (relative risk, 0.31 and 0.48, 
respectively).20 There was never a risk estimate exceeding 1.0 
for any of the 4 new anticoagulants in any of the subcategories 
of bleeding, supporting the safety of these drugs.
For patients with pronounced symptoms of VTE or with a 
large thrombus burden for whom the clinician feels that ini-
tial hospitalization with parenteral anticoagulation is indi-
cated, dabigatran would be an alternative to other approved 
oral anticoagulants when the patient is ready for discharge 
home. Conversely, when the symptoms or thrombosis burden 
on first examination are limited and the patient is suitable for 
outpatient management with only oral therapy, dabigatran as 
opposed to rivaroxaban is not recommended because it has not 
been evaluated for monotherapy.
Conclusions
The 2 studies on the short-term treatment of VTE show that 
dabigatran is noninferior to warfarin for the prevention of 
recurrent VTE. The risk for clinically relevant bleeding or any 
bleeding is significantly lower with dabigatran.
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CLINICAL PERSPECTIVE
This is the second phase III trial with the oral thrombin inhibitor dabigatran for the treatment of acute venous thrombo-
embolism for 6 months. The results of this trial are presented, together with a pooled analysis of both studies. Dabigatran 
was given at a dose of 150 mg twice daily with no dose adjustments. Patients with a creatinine clearance <30 mL/min were 
excluded. Because both trials used initial parenteral anticoagulation also in the dabigatran treatment arm, this drug should 
not be used as monotherapy for acute venous thromboembolism. The similar efficacies of dabigatran and standard treatment 
with warfarin were confirmed. Bleeding was analyzed as major bleeding, major or clinically relevant nonmajor bleeding, 
and any bleeding. For the last 2 categories, the risk was significantly reduced in the dabigatran group in both studies. Major 
bleeding was not significantly reduced in any of the trials separately or pooled when the entire treatment period was included. 
For the treatment period on oral drug only, that is, after the initial week with parenteral therapy but without dabigatran, there 
was also in the pooled analysis a borderline significant reduction of major bleeds. Deaths, adverse events, and acute coronary 
syndromes were similar in both groups. The pattern of lower risk of bleeding is seen with all new anticoagulants compared 
with vitamin K antagonists. Furthermore, here, as in other studies with the new anticoagulants in venous thromboembolism 
or in atrial fibrillation, there is a consistent trend to lower the risk of intracranial bleeding.
Go to http://cme.ahajournals.org to take the CME quiz for this article.
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Definition of Clinically Relevant Nonmajor Bleeding 
At least 1 of the following criteria had to be fulfilled: 
 Spontaneous skin hematoma of at least 25 cm 
 Spontaneous nose bleed of more than 5 minutes duration 
 Macroscopic hematuria, either spontaneous or, if associated with an intervention, lasting 
more than 24 hours 
 Spontaneous rectal bleeding (more than spotting on toilet paper) 
 Gingival bleeding for more than 5 minutes 
 Bleeding leading to hospitalization and/or requiring surgical treatment 
 Bleeding leading to a transfusion of less than 2 units of whole blood or red cells 
 Any other bleeding event considered clinically relevant by the investigator 
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Explanation for Differences Between Number of Events Between the 
Individual Studies and the Pooled Data Analysis 
The sums of the number of events from RE-COVER and RE-COVER II differ slightly for some of the 
outcomes for the following reasons: A) We used the same principles for counting events in RE-
COVER II as we used in RE-COVER, B) In the pooled analysis we took into account new information 
regarding a few events reported from RE-COVER after its publication, and C) Pooled numbers (Table 
3) present the first event that a patient had, and the event therefore contributing to the primary 
endpoint. An explanation of the differences is provided in points 1 to 6, which explains the patients 
that had more than 1 event in this time period. The consequences are the following: 
1. Symptomatic deep vein thrombosis: One patient in each treatment arm had deep vein 
thrombosis (DVT) and pulmonary embolism (PE) on the same day and both were reported. In 
the pooled analysis only 1 event is counted, the PE (as worst case scenario). 
2. Symptomatic non-fatal pulmonary embolism: Two patients in each treatment arm had DVT 
followed by PE, but clearly after the DVT. These were reported as 2 events per patient in the 
studies but only as DVT (the first event) in the pooled analysis. 
3. Death related to pulmonary embolism: Two patients in the dabigatran arm had PE several days 
before the death and were considered in the pooled analyses as non-fatal PE. 
4. Major bleeding: One patient in the warfarin arm had a major bleeding 5 days after stopping 
warfarin for surgery. This was not reported in the primary analysis for RE-COVER but was 
included in the pooled analysis, according to our predefined criteria. This patient also had a 
non-clinically relevant any bleed on-treatment, and prior to the major bleed. 
5. Clinically relevant (non-major) bleeding: One patient in each arm had an event that occurred 
before the first intake of any study drug, reported in the individual studies but not in the pooled 
analysis. 
6. Any bleeding, not clinically relevant: Three events in the warfarin arm in RE-COVER occurred 
in patients, who were rolled over and re-randomized to a study on extended treatment with 
dabigatran or warfarin. Two events were definitely or most likely after this time point and 
therefore not included in the pooled analysis. One event had an unknown time, and is included 
in the pooled analysis. 
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7. In the RE-COVER study there were 2: Any bleeding events on dabigatran versus 3 events 
on:warfarin after 6 months and prior to last medication plus 6 days, which are included here but 
not in the previous publication. Any other differences between original publication of RE-
COVER1 and this one are accounted for by the censoring rule regarding open label 
anticoagulants. This rule was applied to RE-COVER1 bleeding results, but not to RE-COVER 
II and not to the analysis of the pooled data.  
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Supplemental Figure 1. Study flow 
 2589 patients randomized
1293 allocated to dabigatran 1296 allocated to warfarin 
14 did not receive study drug 7 did not receive study drug
1279 included in the
modified intention 
to treat analysis 
1289 included in the 
modified intention 
125 stopped follow-up early 
   47 for adverse event 
   31 for non-adherence 
   11 for loss to-follow-up 
   32 for withdrawal of consent 
   4 for other reasons 
116 stopped follow-up early 
   44 for adverse event 
   26 for non-adherence 
   6 for loss to-follow-up 
   39 for withdrawal of consent 
  1 for other reasons
1279 analyzed for efficacy 
1280 analyzed for safety 
1289 analyzed for efficacy 
1288 analyzed for safety 
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Supplemental Figure 2. Hazard ratios with dabigatran for the primary efficacy outcome in 
predefined subgroups. Pooled analysis of RE-COVER1 and RE-COVER II 
The dotted grey line represents overall treatment effect to the plot (hazard ratio of 1.09). 
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